Trabectedin, gemcitabine, and dacarbazine for advanced leiomyosarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your diagnosis is leiomyosarcoma that is advanced and cannot be fully removed or has metastasized
- Your cancer has been treated before, and there is measurable disease on scans
- You are well enough to do daily activities (performance status 0–2) and expect to live at least 3 months
- Your blood, kidney, and liver tests are within allowed ranges
- You can consent and will be able to attend study visits; if you can become pregnant, you must use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two drugs—gemcitabine (a chemotherapy drug) and nab-sirolimus (a targeted therapy)—for people with advanced soft-tissue sarcoma or leiomyosarcoma, especially those whose tumors have a specific genetic change in the TSC2 or TSC1 genes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
Hear when a new Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.